Biomarin Pharmaceutical (BMRN) Net Equity Issued and Repurchased (2012 - 2015)

Biomarin Pharmaceutical (BMRN) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $888.3 million in Q1 2015.

• Quarterly Net Equity Issued and Repurchased rose 655.96% year-over-year to $888.3 million in Q1 2015, while the trailing twelve-month figure through Dec 2015 was $888.3 million (up 656.2% YoY) and the FY2016 annual result came in at $712.9 million, down 19.74% from the prior year.
• Net Equity Issued and Repurchased grew to $888.3 million in Q1 2015, from -$36000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $888.3 million in Q1 2015 to a low of -$36000.0 in Q2 2014.
• A 3-year average of $310.3 million and a median of $176.5 million in 2012 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 655.96% in 2015, down 655.96% in 2015.
• Tracing BMRN's Net Equity Issued and Repurchased over 3 years: stood at $235.5 million in 2012, then plunged by 100.02% to -$36000.0 in 2014, then jumped by 2467480.56% to $888.3 million in 2015.
• The last three Net Equity Issued and Repurchased figures came in at $888.3 million (Q1 2015), -$36000.0 (Q2 2014), and $117.5 million (Q1 2014), per Business Quant data.